I’m taking a short break over the summer to rest, recharge, and make sure I can continue bringing you my best. I’ll be back with brand-new content on Monday, August 31—until then, you can stay connected through Dr. Dan’s Empowerment Hub or book a one-on-one consultation if you need support.
New clinical trial data on orforglipron reveals a biological ceiling that every person on GLP-1 medications needs to understand. I’m breaking down the ATTAIN-MAINTAIN trial findings, explaining what the 15% threshold means for long-term weight management, and identifying exactly who is — and isn’t — a strong candidate for the transition to the Ozempic pill.
The SURMOUNT MAINTAIN trial has delivered the most compelling evidence yet that obesity requires long-term management — not a finish line. New data reveals exactly what happens to your results at every dose decision, and the numbers make the choice undeniable.
Retatrutide is a triple-action therapy targeting GLP-1, GIP, and glucagon receptors simultaneously — a fundamentally different design from current treatments. Early clinical data reveals significant liver-fat reductions and an unexpected paradox: a receptor long assumed to raise blood sugar instead helps mobilize stored fat and support resting metabolism.
TRIUMPH-1 Phase 3 trial data reveals retatrutide achieved up to 30% body weight loss — outperforming bariatric surgery benchmarks without a single incision. I’m breaking down the full efficacy numbers, safety signals, and what this triple-hormone agonist means for your weight management options right now.
Most people on Wegovy aren’t rapid responders — and the viral 28% weight loss headline from the STEP UP trial only tells half the story. Learn my 4-step Steady-Winner Strategy designed for the 70% who are playing the long game.
Discover why the most common weight loss approach — cutting calories, carbs, and joy — is actually triggering your brain’s ancient famine alarm and working against your GLP-1 medication. I break down my counterintuitive Stack & Add Plan: five steps that work with your biology to protect muscle, outsmart metabolic adaptation, and finally walk through the door your medication opened.
Foundayo (orforglipron) is the first oral GLP-1 medication approved for weight loss — but the clinical trial data reveals a meaningful efficacy gap compared to current injectable options. I break down the ATTAIN-1 trial results, the liver metabolism factor most reviews miss, and my practical framework for deciding whether to start or switch.
Healing peptides like BPC-157 and TB-500 are being marketed as the cutting-edge, natural alternative to GLP-1 medications — but the clinical reality tells a very different story. I break down the Buy-In Effect, the real safety risks of unregulated peptides, and four evidence-based steps that actually protect your progress.
GI side effects on Wegovy or Zepbound are not proof the medication is working — they’re a signal your protocol needs adjusting. My 6-step GI Stability Protocol will give you a concrete, pharmacist-backed framework to manage nausea and stop the guesswork.
Calculate your daily calorie and protein targets to help you achieve your weight goals.
Calculate your daily calorie and protein targets to help you achieve your weight goals.
